Background and Purpose-Our recently proposed point scoring model includes the widely-used Spetzler-Martin (SM)-5 variables, along with age, unruptured presentation, and diffuse border (SM-Supp). Here we evaluate the SM-Supp model performance compared with SM-5, SM-3, and Toronto prediction models using net reclassification index, which quantifies the correct movement in risk reclassification, and validate the model in an independent data set. Methods-Bad outcome was defined as worsening between preoperative and final postoperative modified Rankin Scale score. Point scores for each model were used as predictors in logistic regression and predictions evaluated using net reclassification index at varying thresholds (10%-30%) and any threshold (continuous net reclassification index Ͼ0).
T he Spetzler-Martin (SM) 5-point grading scale is the most widely accepted surgical risk prediction tool for brain arteriovenous malformations, although other models have been proposed. [1] [2] [3] [4] [5] [6] We recently developed a simple point scoring model that incorporates SM angiographic variables but supplements with additional clinical factors (SM-Supp) to improve outcome prediction and demonstrated improved discrimination over SM-5 using area under the receiver operating characteristic curve (AUROC). 7 Here we extend our previous work by comparing SM-Supp performance with other models using the net reclassification index (NRI) and validating the model in an independent data set.
Methods
We included consecutive patients with brain arteriovenous malformation who underwent microsurgical resection between 2000 and 2010 with at least one postoperative visit and no missing outcome data. The development data set consisted of 300 patients with brain arteriovenous malformation treated by a single neurosurgeon (M.T.L.) between 2000 and 2007. 7 The primary validation data set consisted of 117 patients (67 new M.T.L. cases between 2007 and 2010; 50 cases from other neurosurgeons between 2000 and 2010) with no missing data. We also included data from a larger validation data set (nϭ183) for which we multiply imputed missing angiographic data (provided in the online-only Data Supplement).
Outcome was change between preoperative and last postoperative modified Rankin Scale score 8 dichotomized into Ͼ0 (bad outcome) versus Յ0 (good outcome). 7 Predictors included age at surgery, sex, nonhemorrhagic presentation, arteriovenous malformation size, any deep venous drainage, eloquence, diffuse border, and time from surgery to last postoperative modified Rankin Scale assessment (days). SM-5, 1 SM-3, 6 Toronto, 5 and SM-Supp 7 scores are defined in online-only Data Supplement Table I. NRI 9, 10 was used to evaluate model performance and quantifies the correct movement in risk reclassification when comparing predictions between 2 models at various risk thresholds (10%-30%) or any threshold (continuous, cNRI Ͼ0). 10 NRI was compared by combining one-sided McNemar tests across outcomes using the Fisher method. 11 We derived bootstrap 95% CI for cNRI using 1000 replications.
Results
Characteristics were similar between development and validation data sets (PϾ0.05; Table 1; online-only Data Supplement Table II ). Outcomes were bad for 73 (24%) and good for 227 (76%) patients in the development data set. In the validation data set, outcomes were bad for 39 (21%) and good for 144 (79%) patients.
In the development data set, NRI showed improvement in reclassification of 9% to 25% with SM-Supp than SM-5 over all threshold values (Table 2) . A greater net gain was observed at lower thresholds for good and at higher thresholds for bad outcomes. For example, at 15% risk threshold, 85 of 300 (28%) were reclassified into different risk categories. Net gain in reclassification was Ϫ6.8% for those with bad outcomes and 27% for those with good outcomes (NRIϭ0.205, PϽ0.001). Thus, patients with good outcomes were 21% more likely to move down a risk category than up compared with patients with bad outcomes.
Because risk categories for brain arteriovenous malformation surgical outcome are not well established, we also calculated the cNRI comparing SM-Supp to SM-5. The cNRI was 64% (95% CI, 39%-89%; PϽ0.001) with a net gain of 26% in those with good outcomes and 37% in those with bad outcomes (Table 2 ). Thus, 64% had predicted risks reclassified in the correct direction with SM-Supp. Results were similar when comparing SM-Supp with SM-3 (cNRIϭ67%; 95% CI, 41%-93%) and with Toronto (cNRIϭ61%; 95% CI, 37%-85%). Scatterplots of predicted probabilities ( Figure) by good and bad outcomes reflected a greater proportion of patients with correct assignments using the SM-Supp model compared with SM-5 ( Figure A) , SM-3 ( Figure B) , or Toronto models ( Figure C ). In the validation data set, the SM-Supp model again correctly reclassified a greater proportion of patients versus SM-5 (cNRIϭ82%; 95% CI, 43.6%-121%), SM-3 (cNRIϭ85%; 95% CI, 44.7%-126%), and Toronto models (cNRIϭ69%; 95% CI, 26.4%-121%).
Consistent with NRI results, the SM-Supp model yielded better discrimination and highest AUROC than all other models (online-only Data Supplement Figure I ) in development (AUROCϭ0.76, PϽ0.001) and validation (AUROCϭ 0.77, Pϭ0.402) data sets.
Discussion
The SM-Supp model performed equally well in predicting outcomes in an independent data set and consistently showed better risk reclassification and discrimination. For example, Ͼ60% of patients were correctly reclassified as having higher risk for those with bad outcomes and lower risk for those with good outcomes compared with each of SM-5, SM-3, or Toronto models.
Direct comparisons with other models 2-5 are difficult because outcome measures and time points assessed differ among studies, for example, we examined change in outcome, which takes into account preoperative state. Only Spears et al 5 compared performance of their prediction model to SM-5 using modified Rankin Scale and AUROC, showing good discrimination and performance (AUROCϭ0.80). 5 Our model showed equally high discrimination in both development (AUROCϭ0.76) and validation data sets (AUROCϭ0.77).
Although the SM-Supp model derives from a single neurosurgeon and referral institution, we provide an independent validation using the NRI and include cases treated by other neurosurgeons in the largest series to date. However, further validation in external settings would be useful to assess generalizability and clinical use. A limitation of all scoring systems is dealing with missing data. In our full validation data set (nϭ183), 34% were missing angiographic data for SM-Supp, 36% for Toronto, and 13% for SM-5 and SM-3 scores. One way of accommodating missing data are through multiple imputation (see the online-only Data Supplement). Prospective studies planning to use SM-Supp should have minimal issues with missing data: all variables should be available from angiograms and MRI, which are standard for diagnostic evaluation and pretreatment planning, or from records at clinic visits.
In conclusion, the SM-Supp model performs better than current prediction models and should be considered for use in clinical practice. An online calculator is provided to assist clinicians (http://avm.ucsf.edu/healthcare_pro/). 
Sources of Funding

Supplemental Methods
We evaluated model performance in two validation cohorts. The primary validation dataset consisted of 117 patients with no missing data; details included in the paper. The larger "imputed" validation dataset consisted of 183 patients, which included the 117 patients with no missing data plus an additional 66 patients who had outcome data but were missing data for one or more angiographic predictors needed to construct the point scores (3 missing predictors for Toronto score, 40 missing predictors for both Toronto and SM-Supp scores, and 23 missing predictors for all 4 models). These were all outside surgical cases referred to our institution for other treatment or evaluation (i.e., not treated by UCSF neurosurgeon) and captured in our prospective BAVM registry, but images were not available to extract the necessary angiographic information. In order to use all the data from 183 patients, we performed multiple imputations from the entire cohort (both development and validation datasets), using the imputation by chained equations algorithm implemented in Stata SE v11.1 (StataCorp LP). We generated 20 datasets and filled in missing values by drawing from the conditional density of the missing variables given the other known variables. Validation diagnostics were performed and the pooled results were analyzed using the method described by Rubin (1987 (14) 25 (14) 4 33 (11) 9 (8) 20 (11) 5 29 (10) 12 (10) 20 (11) * Multiple imputations were performed to fill in missing data for predictors using data from both the development and validation cohorts.
Supplemental Table S2. Demographic and angiographic characteristics of patients included in the model development and validation cohorts.
Overall, characteristics were similar between those in the development and validation datasets (P>0.05), including distribution of SM-5 (P=0.38), SM-Supp (P=0.30), and baseline MRS scores (P=0.17). There were slight differences in characteristics between those with and without imputed data in the validation datasets, suggesting potential bias when restricting to those with complete data only. For example, unruptured presentation data was available on everyone, yet the percentage was lower when restricting the validation cohort to the 117 patients with no missing data (43%) compared to the full, imputed validation dataset (55%) and the development dataset (51%).
Supplemental Figure
Supplemental Figure S1 . Area under the Receiver Operating Characteristic Curve analysis demonstrating greater predictive accuracy for the Spetzler Martin-Supplemented (SMSupp) model compared to SM-5, SM-3, and Toronto models for A) development dataset (n=300), B) 10-fold cross-validated development dataset (n=300), C) independent validation dataset (n=117), and D) imputed validation dataset (n=183) 
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S1-A.
The SM-Supp model did a better job at discriminating outcomes compared to other models in the development dataset, with the highest AUROC (0.76). There was a significant difference in AUROC (P<0.001), and SM-Supp perfomed significantly better than each of the other models (all pairwise P<0.001). 
chi2(3) = 22.37 Prob>chi2 = 0.0001 S1-B. We performed 10-fold cross validation in the development dataset to compare performance of each prediction model. We used 90% of the data to obtain estimates from the corresponding point score models and predicted outcomes in the remaining 10% of the sample, repeating the process 10 times so that no one was used both in the testing and prediction stage at the same time. Cross-validated AUROC results were similar to observed data indicating that the SM-Supp model was not overly optimistic, and performed significantly better than all other models and had the highest AUROC (0.74, P<0.001).
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Ho: area(mod_SMSupp) = area(mod_SM5) = area(mod_SM3) = area(mod_Toronto) chi2(3) = 2.94 Prob>chi2 = 0.4016 S1-C. All models did a better job at predicting outcomes in the independent validation dataset of 117 patients, with higher AUROC measures than the development cohort (S1-A). The SMSupp model still had the highest AUROC (0.77), although differences between AUROC are no longer significant (P=0.40). 
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S1-D.
In the imputed validation dataset (n=183), the SM-Supp model predicted outcomes equally well and better than other prediction models with the highest AUROC (0.71). The AUROC for SM-5, SM-3, and Toronto models are more similar to the development cohort (S1-A and S1-B), suggesting a potentially biased subset when restricting the validation dataset to the 117 patients with no missing data (S1-C).
